Background: Adjuvant trastuzumab is the standard of care for patients with HER2
overexpressing breast cancer, but use of trastuzumab may lead to cardiotoxicity. Our goal …

128 Background: A recent study suggests that cardiotoxicity from adjuvant trastuzumab (T-
mab) is associated with inadequate cardiac monitoring (Ng et al. SABCS 2012). Few studies …

Background: Trastuzumab has improved patient outcomes in HER2+ breast cancer (BC) but
carries a risk of cardiotoxicity. Routine cardiac imaging is recommended for advanced breast …

Background Significant and symptomatic cardiac comorbidity is a contraindication to
adjuvant trastuzumab in breast cancer patients. However, some patients with asymptomatic …

Adjuvant therapy with trastuzumab is standard in women with early stage HER‐2‐positive
breast cancer. Following reports of left ventricular (LV) dysfunction with trastuzumab in …

Introduction. We assessed the incidence and timing of first cardiac events, impact on
trastuzumab prescription, and role of left ventricular ejection fraction (LVEF) monitoring in …

Background Trastuzumab-associated cardiotoxicity remains an issue for patients with HER2-
positive breast cancer. This pooled analysis of 3 adjuvant trials investigated the incidence …

Management of human epidermal growth factor receptor-2-positive (HER2+) breast cancer
patients includes the combination of adjuvant chemotherapy and trastuzumab. A meta …

Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may
increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not …

Purpose Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment
may differ in real-world practice versus randomized trials. We investigated cardiac events in …